



HAL
open science

Why promoting a COVID-19 vaccine booster dose?

Paul Loubet, Didier Laureillard, Aurélie Martin, R. Larcher, Albert Sotto

► **To cite this version:**

Paul Loubet, Didier Laureillard, Aurélie Martin, R. Larcher, Albert Sotto. Why promoting a COVID-19 vaccine booster dose?. *Anaesthesia Critical Care & Pain Medicine*, 2021, 40 (6), pp.100967. 10.1016/j.accpm.2021.100967 . hal-03498752

HAL Id: hal-03498752

<https://hal.science/hal-03498752>

Submitted on 21 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Paul Loubet*, Didier Laureillard, Aurélie Martin,
Romaric Larcher, Albert Sotto
Department of infectious and Tropical Diseases, CHU Nîmes,
University of Montpellier, Nîmes, France

*Corresponding author
E-mail address: paul.loubet@chu-nimes.fr (P. Loubet)

Why promoting a COVID-19 vaccine booster dose?

ARTICLE INFO

Keywords:
COVID-19
Vaccine
Booster dose
SARS-CoV-2

French COVID-19 vaccination campaign started on the 27th of December 2020, first with long-term care facility residents and health care workers, then progressively extended by age and risk factors for severe COVID-19 to all adults on the 31st of May 2021 and to 12-17-year-olds on the 15th of June 2021. As of the 17th of September 2021, more than 50 million French people (75% of the total population) have received at least one dose of the four European Medicine Agency approved COVID-19 vaccines: mRNA BNT162b2 (Comirnaty[®], Pfizer-BioNTech), mRNA-1273 (Spikevax[®], Moderna), ChAdOx1 nCoV-19 (Vaxzevria[®], AstraZeneca-Oxford University), and Ad26.COV2-S (COVID-19 Vaccine Janssen[®], Janssen-Cilag).

French Health authorities approved a booster dose of mRNA vaccine (independently of the vaccine received in the primary scheme) for those over 65 and those at high risk of developing severe forms of COVID-19. This booster campaign has started to roll out on the 1st of September 2021. More recently, on the 6th of October 2021, the recommendation was extended to healthcare professionals and relatives of immunocompromised patients.

A distinction needs to be made between “booster” and “additional” doses. “Booster” doses are for people who responded adequately to primary vaccination in order to restore protection after it would have waned. “Additional” doses concern immunocompromised people who did not respond adequately to the standard primary vaccination. These additional doses have been administered to severely immunocompromised people since the 11th of April in France.

Expected objectives of a booster dose

The choice for a booster campaign mostly relies on the association of the spread of Delta variant of concern (VOC) and first available data on the waning of humoral immunity following vaccination.

Several studies have shown that COVID-19 vaccination is able to induce a robust immune response towards the spike protein of SARS-CoV-2 with the generation of T and B cell-antibody

responses. However, the duration of this immune response is still unknown and it is not clear whether a waning of neutralising antibody levels would occur as it has been reported around six months post-infection [1,2].

A recent study compared antibody levels between age groups and reported lower levels of spike-specific, and especially neutralising antibodies, in the older adults (over the age of 80) compared to younger individuals after vaccination with Comirnaty[®] (Pfizer-BioNTech) [3]. This suggests that older adults may have a weaker immune response to the vaccine and thus a faster antibody decline, which has been underlined in a cohort of 3808 health care workers in Israel, showing a substantially lower rate of IgG antibodies in those aged 65 or older compared to those 18 to less than 45 years of age, six months after receiving the second dose of the Comirnaty[®] (Pfizer-BioNTech) vaccine [4].

However, it is still not known what antibody levels are needed to protect from severe, symptomatic disease or infection with SARS-CoV-2. Additionally, these studies did not consider the impact of vaccine generated memory cells on the duration of protective immunity.

The efficacy of the Spikevax[®] vaccine (Moderna) against COVID-19 and severe COVID-19 has been showed to be maintained for more than 5 months after the second dose among all subgroups, including those at risk for severe complications [5]. Nonetheless, in these trials, the vaccine effectiveness was not reported after 5 months and impact of SARS-CoV-2 VOC was not assessed, since circulation of the variants was low.

The recently published data from the original randomised controlled clinical trial of Comirnaty[®] (Pfizer-BioNTech) confirmed that the vaccine effectiveness against laboratory-confirmed COVID-19 remained high for up to six months after receiving the primary vaccination series (*i.e.*, two-dose vaccine scheme). Nevertheless, a gradual decline was observed from the peak vaccine effectiveness of 96.2% (95% CI: 93.3–98.1) between seven days and two months after the second dose to the period between two months and four months after the second dose (VE = 90.1%; 95% CI: 86.6–92.9), and the period between four months and the data cut-off (vaccine effectiveness = 83.7%; 95% CI: 74.7–89.9) [6].

A test-negative case-control study from England in the general population recently published as a preprint by Public Health England compared the incidence of COVID-19 (560,000 Alpha variant cases, 894,000 Delta variant cases, 21,000 hospitalisations, 4,500 deaths) in 1.5 million vaccinated individuals (Vaxzevria[®] or Comirnaty[®](Pfizer-BioNTech)) versus 3.7 million unvaccinated individuals. In this study, >20 weeks after the second dose, the rate of protection against COVID-19 (symptomatic and asymptomatic

had significantly decreased (compared to protection rates from phase III trials): 47.3% (CI 95%: 45.0–49.6) for Vaxzevria[®] (AstraZeneca–Oxford University) and 69.7% (68.7–70.5) for Comirnaty[®] (Pfizer–BioNTech). Importantly, this decrease was not show in COVID-19-related hospitalisation: 77% (70.3–82.3) for Vaxzevria[®] and 92.7% (90.3–94.6) for Comirnaty[®] (Pfizer–BioNTech); and COVID-19 related-death: 78.7% (52.7–90.4) for Vaxzevria[®] (AstraZeneca–Oxford University) and 90.4% (85.1–93.8) for Comirnaty[®] (Pfizer–BioNTech), respectively.

These results have been confirmed by two other large studies in Qatar [7] and in the USA [8].

Furthermore, the currently dominant Delta VOC, associated with higher transmissibility, exposure to higher viral loads, as well as partial escape from cellular and humoral responses can have a negative impact on protective immunity. The same data from Public Health England confirmed the decreased effectiveness following two doses of Vaxzevria[®] (AstraZeneca–Oxford University) or Comirnaty[®] (Pfizer–BioNTech) against Delta VOC compared to the Alpha VOC-related infections more marked with Vaxzevria[®] (AstraZeneca–Oxford University) [9] without real differences between variants on COVID-19-related hospitalisations and deaths [10].

Effectiveness of the booster dose

First immunological data showed that a booster shot of ARNm vaccine induced substantially higher neutralising antibody titres against the wild type SARS-CoV-2 virus as well as Beta and Delta variants, compared to levels reported after the second dose of vaccine. Indeed, neutralisation Geometric Mean titres following dose 3 of Comirnaty[®] (Pfizer–BioNTech) vaccine increased to more than 5 times as high (in 18-to-55-year-olds) and to more than 7 times as high (in 65-to-85-year-olds) against wild-type virus, more than 15 times as high (in 18-to-55-year-olds) and to more than 20 times as high (in 65-to-85-year-olds) against Beta variants and more than 5 times as high (in 18-to-55-year-olds) and to more than 12 times as high (in 65-to-85-year-olds) against Delta variants [11]. Similarly, data on Spikevax[®] (Moderna) showed that a booster dose increased neutralisation titres against wild-type variants (3.8 times), beta variants (32 times) and delta variant (42 times) compared to post dose 2 titres [12].

To date, there are no data from randomised controlled trial on booster doses effectiveness. However, first real-life effectiveness data from Israel compared the occurrence of COVID-19 and severe COVID-19 in a booster group (at least 12 days after Comirnaty[®] (Pfizer–BioNTech) dose 3) and a non-booster group in a large study including 1.14 million people aged 60 years and older at least 5 months after dose 2. The rate of confirmed infection was lower in the booster group than in the non-booster group by a factor of 11.3 (95% confidence interval [CI], 10.4 to 12.3) and the rate of severe COVID-19 was lower by a factor of 19.5 (95% CI, 12.9 to 29.5). Adverse events after booster dose were similar to those after dose 2. According to these data, the booster dose might prevent 86.6 all forms of infection per 100,000 patients and 7.5 severe forms per 100,000 patients [13]. These data suggest that the additional protection afforded by the booster dose is therefore considerably greater against mild to moderate forms than against severe forms.

In conclusion, the decrease in vaccine protection over time appears to be real for all forms of infection starting from the 6th month after the second injection, but does not appear to have a real impact on the risk of COVID-19-related hospitalisation or death. The decrease in protection is more pronounced in people older than 65 years and in those at higher risk of severe COVID-19. The usefulness of a booster dose is still debated but is recommended in a growing number of countries in the elderly, those at higher risk of

Table 1

	2 weeks to 2 months efficacy against COVID-19** (Wild type strains)	> 4 months efficacy* (Wild Type strain)		> 5 months effectiveness** (Delta variant)		Fold of increase in neutralising antibody titre after the receipt of a booster dose at Month 6***		
		COVID-19	COVID-19-related hospitalisation	COVID-19	COVID-19 related-hospitalisation	Wild Type	Beta	Delta
Comirnaty [®] (Pfizer–BioNTech)	96.2% (95%CI [93.3–98.1])	83.7% [74.7–89.9]	96.7% [80.3–99.9]	69.7% [68.7–70.5]	5 (18–55 years old) 7 (65–85 years old) 3.8 [#]	15 (18–55 years old) 20 (65–85 years old) 32 [#]	5 (18–55 years old) 12 (65–85 years old) 42 [#]	
Spikevax [®] (Moderna)	91.8% [86.9–95.1]	92.4% [84.3–96.8]	98.2% [92.8–99.6]	Not available	Not available	Not available	Not available	
Vaxzevria [®] (AstraZeneca–Oxford University)	74.0% [65.3–80.5]	Not available	98.2% [92.8–99.6]	47.3% [45.0–49.6]	Not available	Not available	Not available	
COVID-19 Vaccine Janssen [®] , Janssen–Cilag	66.1% [55.0–74.8]	Not available	Not available	Not available	Not available	Not available	Not available	

##Data not published.

* After the receipt of Dose 2, data from randomised controlled trials.

** After the receipt of Dose 2, data from “real-life” cohorts.

*** Compared to neutralising antibody level after Dose 2.

Booster dose was half the dosage of D1/D2.

exposition or to contract severe forms. Upcoming data on vaccine duration of protection and real-life efficacy and safety of booster doses will add evidence on its hypothetical interest in the general population. Finally, it must be underlined that the priority should remain to vaccinate all eligible individuals not yet vaccinated with the recommended dose regimen (Table 1).

Funding

Dr Loubet reports consulting fees from Pfizer, AstraZeneca, Sanofi and GSK and non-financial support from Sanofi Pasteur and Pfizer outside the submitted work.

Declaration of Competing interests

Other authors do no report competing interest.

References

- [1] Widge AT, Roupael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N Engl J Med* 2021;384:80–2.
- [2] Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. *N Engl J Med* 2021;384:2259–61.
- [3] Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. *Clin Infect Dis* 2021 [cité 2021 sept 30]; Available from: <https://doi.org/10.1093/cid/ciab381>.
- [4] Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* 2021 [cité 2021 oct 14]; Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2114583>.
- [5] El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021;0. null.

- [6] Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021;0. null.
- [7] Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021 [cité 2021 oct 14]; Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2114114>.
- [8] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* 2021 [cité 2021 oct 14]; Available from: <https://www.sciencedirect.com/science/article/pii/S0140673621021838>.
- [9] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021;385:585–94.
- [10] Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. *N Engl J Med* 2021;0. null.
- [11] Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med* 2021;0. null.
- [12] Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* 2021 [cité 2021 sept 24]; Available from: <https://www.nature.com/articles/s41591-021-01527-y>.
- [13] Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med* 2021;0. null.

Paul Loubet*, Didier Laureillard, Aurélie Martin,
Romaric Larcher, Albert Sotto
*Department of infectious and Tropical Diseases, CHU Nîmes,
University of Montpellier, Nîmes, France*

*Corresponding author
E-mail address: paul.loubet@chu-nimes.fr (P. Loubet)